

1/13






Figure 1

2/13



**Figure 2**

3/13





Figure 3

4/13



SAC stimulation for 24 hours

Figure 4

5/13




Figure 5

6/13

## Prolongation of graft survival induced by treatment with GCS





Figure 6

7/13


**Pretreatment of BALB/c splenic  
cells with GCS reduces PHA-  
stimulated proliferation**



**Figure 7**

8/13

# **GCS-pretreated responder or stimulator cells suppressed MLR (BALB/c anti-C57/B6)**



**Figure 8**



9/13

### GCS-pretreated DC reduced anti-allo T lymphocyte response




Figure 9

10/13

GCS affects monocytes  
differentiate to dendritic cells





Figure 10

11/13


**IDO-inhibitor (1-methyl-TRP) prevents GCS-induced suppression of PHA stimulation**



**Figure 11**

12/13

**IDO-inhibitor (1-methyl-TRP) prevents GCS-pretreated monocyte-induced, PHA stimulated T cell apoptosis**




**PHA stimulation (day 6)**

**Figure 12**

13/13

**IDO-inhibitor (1-methyl-TRP) prevents GCS-pretreated monocyte-induced, recall Ags stimulated T cell apoptosis**



**Recall antigen stimulation (day 6)**

**Figure 13**